Characterization of somatostatin receptor 2 and 5 expression in operable hepatocellular carcinomas.
Hepatogastroenterology
; 59(119): 2054-8, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-22640914
ABSTRACT
BACKGROUND/AIMS:
Somatostatin analog improves survival in patients with advanced hepatocellular carcinoma by interacting with its specific receptor 2 and 5. However, expression of somatostatin receptor (SSTR) in operable HCC is still unclear. In this study, we analyzed the expression of SSTR-2 and -5 in HBV-related HCC and compared its clinicopathological features and follow-up data.METHODOLOGY:
Seventy six patients with HCC were enrolled. SSTR-2 and -5 expression was investigated by QPCR and immunohistochemistry in all the samples. Furthermore, the association between gene expression and survival was analyzed.RESULTS:
Compared to surrounding cirrhotic tissues, mRNA levels of SSTR-2 and -5 in HCCs were significantly reduced. Seventy six HCC patients were divided into two groups according to SSTR-2 and 5 expression profiles. Both groups were well balanced with respect to baseline characteristics. According to univariate analysis, the mean survival time was longer in the HIGH SSTR-2/5 expression group. Multivariate Cox analysis showed that tumor expression level of SSTR-2 can be used as an independent prognostic marker of HCC as well as tumor TNM stage.CONCLUSIONS:
Downregulation of SSTR transcription may result in loss of a tumor suppressive. Characterization of SSTR expression can be used as a useful parameter to evaluate the prognosis of HCC.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
Receptores de Somatostatina
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Hepatogastroenterology
Año:
2012
Tipo del documento:
Article
País de afiliación:
China